Author

Nathan Morris 1

1 Eli Lilly and Company,Indianapolis,United Sta

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky, Remo Panaccione, James D Lewis, Bruce E. Sands, Toshifumi Hibi, Scott D. Lee, April Naegeli, Mingyang Shan, Linden Green, Nathan Morris, Vipin Arora, Alison Potts Bleakman, Ruth Belin, Simon Travis

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Marla C. Dubinsky, Scott D. Lee, Remo Panaccione, Maria T. Abreu, Severine Vermeire, Trevor Lissoos, Nathan Morris, Vipin Arora, Mingyang Shan, April Naegeli, Bruce E. Sands

EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

Silvio Danese, Axel Dignass, Katsuyoshi Matsuoka, Marc Ferrante, Millie Long, Isabel Redondo, Theresa Hunter Gibble, Richard Moses, Nathan Morris, Xingyuan Li, Catherine Milch, Maria T. Abreu

EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

Geert R. D'Haens, Taku Kobayashi, Nathan Morris, Trevor Lissoos, Amy Hoover, Xingyuan Li, Vipin Arora, Catherine Milch, William J. Sandborn, Bruce E. Sands

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Fernando Magro, Rish Pai, Taku Kobayashi, Vipul Jairath, Florian Rieder, Isabel Redondo, Trevor Lissoos, Nathan Morris, Mingyang Shan, Laurent Peyrin-Biroulet

MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE TRIALS

Bruce E. Sands, Brian G. Feagan, Theresa Hunter Gibble, Kristina Traxler, Nathan Morris, Xingyuan Li, Stefan Schreiber, Vipul Jairath, Alessandro Armuzzi

MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Bruce E. Sands, Brian G. Feagan, Theresa Hunter Gibble, Kristina Traxler, Nathan Morris, Xingyuan Li, Stefan Schreiber, Vipul Jairath, Alessandro Armuzzi

SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

Axel Dignass, Silvio Danese, Katsuyoshi Matsuoka, Marc Ferrante, Millie Long, Isabel Redondo, Theresa Hunter Gibble, Richard Moses, Xingyuan Li, Nathan Morris, Catherine Milch, Maria T. Abreu

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Britta Siegmund, Bruce E. Sands, Karen Hamrick Samaan, Xingyuan Li, Nathan Morris, Theresa Hunter Gibble, Isabel Redondo, Trevor Lissoos, Geert R. D'Haens

Item 1 - 9 / 9
1